Literature DB >> 19556031

Acute metformin overdose: examining serum pH, lactate level, and metformin concentrations in survivors versus nonsurvivors: a systematic review of the literature.

Damon M Dell'Aglio1, Louis J Perino, Ziad Kazzi, Jerome Abramson, Michael D Schwartz, Brent W Morgan.   

Abstract

STUDY
OBJECTIVE: Metformin is known to cause potentially fatal metabolic acidosis with an increased lactate level in both overdose and therapeutic use. No association between mortality and serum pH, lactate level, or metformin concentrations, though intuitive, has yet been described. This systematic literature review is designed to evaluate the association between mortality and serum pH, lactate level, and metformin concentrations in acute metformin overdose.
METHODS: We reviewed the literature by using the MEDLINE, EMBASE, CINAHL, and TOXNET databases for cases of metformin overdose with documented mortality data and values of serum pH, lactate level, and metformin concentrations. When available, patient age, patient sex, and whether patients received intravenous sodium bicarbonate therapy or hemodialysis were also analyzed. Cases meeting inclusion criteria were analyzed to determine whether a difference in distribution of nadir serum pH, peak serum lactate level, or peak serum metformin concentrations existed between overdose survivors and nonsurvivors.
RESULTS: We identified 10 articles that had 1 or more cases meeting our inclusion criteria. In total, there were 22 cases of metformin overdose (5/22 died) that met inclusion criteria. No intentional overdose patients died whose serum pH nadir was greater than 6.9, maximum lactate concentration less than 25 mol/L, or maximum metformin concentration less than 50 microg/mL (therapeutic range 1 to 2 microg/mL). Intentional overdose patients with a nadir serum pH less than 6.9 had 83% mortality (5/6), those with lactate concentration greater than 25 mmol/L had 83% mortality (5/6), and those with metformin concentration greater than 50 microg/mL had 38% mortality (5/12). Nadir serum pH and peak serum lactate and metformin concentration distributions in survivors and nonsurvivors revealed that survivors had a median nadir pH of 7.30, interquartile range (IQR) 7.22, 7.36; nonsurvivors, a median nadir pH of 6.71, IQR 6.71, 6.73; survivors, a median peak lactate level of 10.8 mmol/L, IQR 4.2, 12.9; nonsurvivors, a median peak lactate level of 35.0 mmol/L, IQR 33.3, 39.0; survivors, a median peak metformin level of 42 microg/mL, IQR 6.6, 67.6; and nonsurvivors, a median peak metformin level of 110 microg/mL, IQR 110, 110.
CONCLUSION: No cases of acute metformin overdose meeting the study's inclusion criteria were found in which patients with a nadir serum pH greater than 6.9, peak serum lactate concentrations less than 25 mmol/L, or peak serum metformin concentrations less than 50 microg/mL died. Patients with acute metformin overdose who died had much lower serum pH nadirs and much higher peak serum lactate and metformin concentrations than those who survived.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19556031     DOI: 10.1016/j.annemergmed.2009.04.023

Source DB:  PubMed          Journal:  Ann Emerg Med        ISSN: 0196-0644            Impact factor:   5.721


  40 in total

1.  Fatal metformin overdose: case report and postmortem biochemistry contribution.

Authors:  Alessandro Bonsignore; Fulvia Pozzi; Giulio Fraternali Orcioni; Francesco Ventura; Cristian Palmiere
Journal:  Int J Legal Med       Date:  2013-11-08       Impact factor: 2.686

2.  Case Files from the University of California San Diego Health System Fellowship Coma and Severe Acidosis: Remember to Consider Acetaminophen.

Authors:  Janna H Villano; Charles W O'Connell; Binh T Ly; Aaron Schneir
Journal:  J Med Toxicol       Date:  2015-09

Review 3.  Blood lactate concentration after exposure to conducted energy weapons (including TASER® devices): is it clinically relevant?

Authors:  James R Jauchem
Journal:  Forensic Sci Med Pathol       Date:  2013-04-19       Impact factor: 2.007

4.  Metformin inhibits growth and decreases resistance to anoikis in medullary thyroid cancer cells.

Authors:  Joanna Klubo-Gwiezdzinska; Kirk Jensen; John Costello; Aneeta Patel; Victoria Hoperia; Andrew Bauer; Kenneth D Burman; Leonard Wartofsky; Vasyl Vasko
Journal:  Endocr Relat Cancer       Date:  2012-05-24       Impact factor: 5.678

5.  Environment Dictates Dependence on Mitochondrial Complex I for NAD+ and Aspartate Production and Determines Cancer Cell Sensitivity to Metformin.

Authors:  Dan Y Gui; Lucas B Sullivan; Alba Luengo; Aaron M Hosios; Lauren N Bush; Nadege Gitego; Shawn M Davidson; Elizaveta Freinkman; Craig J Thomas; Matthew G Vander Heiden
Journal:  Cell Metab       Date:  2016-10-13       Impact factor: 27.287

6.  Quantification of Low-Level Drug Effects Using Real-Time, in vitro Measurement of Oxygen Consumption Rate.

Authors:  Adam Neal; Austin M Rountree; Craig W Philips; Terrance J Kavanagh; Dominic P Williams; Peter Newham; Gamal Khalil; Daniel L Cook; Ian R Sweet
Journal:  Toxicol Sci       Date:  2015-09-22       Impact factor: 4.849

7.  The Role of Metformin in Metformin-Associated Lactic Acidosis (MALA): Case Series and Formulation of a Model of Pathogenesis.

Authors:  Janna K Duong; Timothy J Furlong; Darren M Roberts; Garry G Graham; Jerry R Greenfield; Kenneth M Williams; Richard O Day
Journal:  Drug Saf       Date:  2013-09       Impact factor: 5.606

8.  'Massive' metformin overdose.

Authors:  Angela L Chiew; Daniel F B Wright; Nicola M Dobos; Kylie McArdle; Ahmed A Mostafa; Annemarie Newth; Michael S Roberts; Geoffrey K Isbister
Journal:  Br J Clin Pharmacol       Date:  2018-04-17       Impact factor: 4.335

Review 9.  Metformin in chronic kidney disease: time for a rethink.

Authors:  James Heaf
Journal:  Perit Dial Int       Date:  2014-04-07       Impact factor: 1.756

Review 10.  Therapeutic Concentrations of Metformin: A Systematic Review.

Authors:  Farshad Kajbaf; Marc E De Broe; Jean-Daniel Lalau
Journal:  Clin Pharmacokinet       Date:  2016-04       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.